247 related articles for article (PubMed ID: 32532810)
1. Immunotargeting of the xCT Cystine/Glutamate Antiporter Potentiates the Efficacy of HER2-Targeted Immunotherapies in Breast Cancer.
Conti L; Bolli E; Di Lorenzo A; Franceschi V; Macchi F; Riccardo F; Ruiu R; Russo L; Quaglino E; Donofrio G; Cavallo F
Cancer Immunol Res; 2020 Aug; 8(8):1039-1053. PubMed ID: 32532810
[TBL] [Abstract][Full Text] [Related]
2. Immunotargeting of Antigen xCT Attenuates Stem-like Cell Behavior and Metastatic Progression in Breast Cancer.
Lanzardo S; Conti L; Rooke R; Ruiu R; Accart N; Bolli E; Arigoni M; Macagno M; Barrera G; Pizzimenti S; Aurisicchio L; Calogero RA; Cavallo F
Cancer Res; 2016 Jan; 76(1):62-72. PubMed ID: 26567138
[TBL] [Abstract][Full Text] [Related]
3. Fighting breast cancer stem cells through the immune-targeting of the xCT cystine-glutamate antiporter.
Ruiu R; Rolih V; Bolli E; Barutello G; Riccardo F; Quaglino E; Merighi IF; Pericle F; Donofrio G; Cavallo F; Conti L
Cancer Immunol Immunother; 2019 Jan; 68(1):131-141. PubMed ID: 29947961
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer stem cell antigens as targets for immunotherapy.
Quaglino E; Conti L; Cavallo F
Semin Immunol; 2020 Feb; 47():101386. PubMed ID: 31932198
[TBL] [Abstract][Full Text] [Related]
5. Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer.
Crosby EJ; Acharya CR; Haddad AF; Rabiola CA; Lei G; Wei JP; Yang XY; Wang T; Liu CX; Wagner KU; Muller WJ; Chodosh LA; Broadwater G; Hyslop T; Shepherd JH; Hollern DP; He X; Perou CM; Chai S; Ashby BK; Vincent BG; Snyder JC; Force J; Morse MA; Lyerly HK; Hartman ZC
Clin Cancer Res; 2020 Sep; 26(17):4670-4681. PubMed ID: 32732224
[TBL] [Abstract][Full Text] [Related]
6. Bovine herpesvirus 4-based vector delivering the full length xCT DNA efficiently protects mice from mammary cancer metastases by targeting cancer stem cells.
Donofrio G; Tebaldi G; Lanzardo S; Ruiu R; Bolli E; Ballatore A; Rolih V; Macchi F; Conti L; Cavallo F
Oncoimmunology; 2018; 7(12):e1494108. PubMed ID: 30524888
[TBL] [Abstract][Full Text] [Related]
7. Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response.
Kodumudi KN; Ramamoorthi G; Snyder C; Basu A; Jia Y; Awshah S; Beyer AP; Wiener D; Lam L; Zhang H; Greene MI; Costa RLB; Czerniecki BJ
Front Immunol; 2019; 10():1939. PubMed ID: 31475002
[TBL] [Abstract][Full Text] [Related]
8. Cystine/glutamate antiporter xCT deficiency reduces metastasis without impairing immune system function in breast cancer mouse models.
Ruiu R; Cossu C; Iacoviello A; Conti L; Bolli E; Ponzone L; Magri J; Rumandla A; Calautti E; Cavallo F
J Exp Clin Cancer Res; 2023 Sep; 42(1):254. PubMed ID: 37770957
[TBL] [Abstract][Full Text] [Related]
9. Glutaminolysis-related genes determine sensitivity to xCT-targeted therapy in head and neck squamous cell carcinoma.
Okazaki S; Umene K; Yamasaki J; Suina K; Otsuki Y; Yoshikawa M; Minami Y; Masuko T; Kawaguchi S; Nakayama H; Banno K; Aoki D; Saya H; Nagano O
Cancer Sci; 2019 Nov; 110(11):3453-3463. PubMed ID: 31444923
[TBL] [Abstract][Full Text] [Related]
10. Heterologous human/rat HER2-specific exosome-targeted T cell vaccine stimulates potent humoral and CTL responses leading to enhanced circumvention of HER2 tolerance in double transgenic HLA-A2/HER2 mice.
Xie Y; Wu J; Xu A; Ahmeqd S; Sami A; Chibbar R; Freywald A; Zheng C; Xiang J
Vaccine; 2018 Mar; 36(11):1414-1422. PubMed ID: 29415817
[TBL] [Abstract][Full Text] [Related]
11. Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms.
Singh JK; Farnie G; Bundred NJ; Simões BM; Shergill A; Landberg G; Howell SJ; Clarke RB
Clin Cancer Res; 2013 Feb; 19(3):643-56. PubMed ID: 23149820
[TBL] [Abstract][Full Text] [Related]
12. Cystine-glutamate antiporter xCT deficiency suppresses tumor growth while preserving antitumor immunity.
Arensman MD; Yang XS; Leahy DM; Toral-Barza L; Mileski M; Rosfjord EC; Wang F; Deng S; Myers JS; Abraham RT; Eng CH
Proc Natl Acad Sci U S A; 2019 May; 116(19):9533-9542. PubMed ID: 31019077
[TBL] [Abstract][Full Text] [Related]
13. DNA vaccines targeting the encoded antigens to dendritic cells induce potent antitumor immunity in mice.
Cao J; Jin Y; Li W; Zhang B; He Y; Liu H; Xia N; Wei H; Yan J
BMC Immunol; 2013 Aug; 14():39. PubMed ID: 23941509
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis.
Croci S; Nanni P; Palladini A; Nicoletti G; Grosso V; Benegiamo G; Landuzzi L; Lamolinara A; Ianzano ML; Ranieri D; Dall'Ora M; Iezzi M; De Giovanni C; Lollini PL
Breast Cancer Res; 2015 May; 17(1):70. PubMed ID: 25997501
[TBL] [Abstract][Full Text] [Related]
15. Vaccine-Induced Memory CD8
Crosby EJ; Gwin W; Blackwell K; Marcom PK; Chang S; Maecker HT; Broadwater G; Hyslop T; Kim S; Rogatko A; Lubkov V; Snyder JC; Osada T; Hobeika AC; Morse MA; Lyerly HK; Hartman ZC
Clin Cancer Res; 2019 May; 25(9):2725-2736. PubMed ID: 30635338
[TBL] [Abstract][Full Text] [Related]
16. [Anti-HER2 vaccines: The HER2 immunotargeting future?].
Ladjemi MZ; Jacot W; Pèlegrin A; Navarro-Teulon I
Pathol Biol (Paris); 2011 Jun; 59(3):173-82. PubMed ID: 19481373
[TBL] [Abstract][Full Text] [Related]
17. Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).
Martin-Castillo B; Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Moreno JM; Corominas-Faja B; Urruticoechea A; Martín ÁG; López-Bonet E; Menendez JA
Cell Cycle; 2013 Jan; 12(2):225-45. PubMed ID: 23255137
[TBL] [Abstract][Full Text] [Related]
18. Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice.
Wang X; Wang JP; Rao XM; Price JE; Zhou HS; Lachman LB
Breast Cancer Res; 2005; 7(5):R580-8. PubMed ID: 16168101
[TBL] [Abstract][Full Text] [Related]
19. An HER2 DNA vaccine with evolution-selected amino acid substitutions reveals a fundamental principle for cancer vaccine formulation in HER2 transgenic mice.
Jones RF; Reyes JD; Gibson HM; Jacob JB; Vaishampayan U; Ratner S; Chen K; Wei WZ
Cancer Immunol Immunother; 2019 Jul; 68(7):1143-1155. PubMed ID: 31177328
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer vaccines delivered by dendritic cell-targeted lentivectors induce potent antitumor immune responses and protect mice from mammary tumor growth.
Bryson PD; Han X; Truong N; Wang P
Vaccine; 2017 Oct; 35(43):5842-5849. PubMed ID: 28916248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]